Novel developments in omega-3 fatty acid-based strategies

Current Opinion in Lipidology

Volumn 22, Issue 6, 2011, Pages 437-444

  Davidson, Michael H ^a   Kling, Douglas ^b   Maki, Kevin C ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b Omthera Pharmaceuticals Inc   (United States)

^c Provident Clinical Research   (United States)

Author keywords

arrhythmias; bioavailability; heart failure; omega 3 fatty acids; platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; OMEGA 3 FATTY ACID ESTER; TRIACYLGLYCEROL;

DIETARY INTAKE; DRUG INDICATION; DYSLIPIDEMIA; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; LOW FAT DIET; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ARRHYTHMIAS, CARDIAC; BIOLOGICAL AVAILABILITY; CORONARY ARTERY DISEASE; FATTY ACIDS, OMEGA-3; HEART FAILURE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 81855194044     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834bd642     Document Type: Review

References (53)

1. Kris-Etherton PM, Harris WS, Appel LJ, Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23:e20-e30.
2. Lovaza Prescribing Information. GlaxoSmithKline, 2010. http://us.gsk.com/products/assets/us-lovaza.pdf [Accessed 16 July 2011].
3. Kling DF, Johnson J, Rooney M, Davidson M. Omega-3 free fatty acids demonstrate more than 4-fold greater bioavailability for EPA and DHA compared with omega-3-acid ethyl esters in conjunction with a low-fat diet: the ECLIPSE study. J Clin Lipidol 2011; 105:231.
4. Maki KC, Dicklin MR, Davidson MH, et al. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy. Am J Cardiol 2010; 105:1409-1412.
5. Maki KC. Fibrates for the treatment of the metabolic syndrome. Curr Atheroscler Rep 2004; 6:45-51.
6. Maki KC, Dicklin MR, Lawless AL, Reeves MS. Omega-3 fatty acids for the treatment of elevated triglycerides. Clin Lipidol 2009; 4:425-437.
7. Chan DC, Watts GF, Barrett PHR, et al. Regulatory effects of HMG CoA reductase inhibitors and fish oils on Apo B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 2002; 51:2377-2386. (Pubitemid 34827385)
8. Chan DC, WattsGF, Mori TA, et al. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr 2003; 77:300-307. (Pubitemid 36133369)
9. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003; 31:1066-1069. (Pubitemid 37305047)
10. Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol 2009; 3:332-340.
11. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108:682-690.
12. Jacobson TA, Soni PN, Glickstein SA, Rowe JD. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol: a critical review. J Clin Lipidol 2011; 105:200-201.
13. Grimsgaard S, Bønaa KH, Hansen JB, Nordøy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerollowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 1997; 66:649-659. (Pubitemid 27366792)
14. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic acid and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71:1085-1094. (Pubitemid 30230554)
15. Nestel P, Shige H, Pomeroy S, et al. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 2002; 76:326-330. (Pubitemid 34804052)
16. Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002; 76:1007-1015. (Pubitemid 35244671)
17. Woodman RJ, Mori TA, Burke V, et al. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care 2003; 26:253. (Pubitemid 36929035)
18. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003; 44:455-463. (Pubitemid 37279692)
19. Egert S, Kannenberg F, Somoza V, et al. Dietary a-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr 2009; 139:861-868.
20. Breslow JL. n-3 fatty acids and cardiovascular disease. Am J Clin Nutr 2006; 83. (Suppl):1477S-1482S. (Pubitemid 44713088)
21. Cottin SC, Sanders TA, Hall WL. The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011; 70:215-231.
22. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009; 54:585-594.
23. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010; 376:540-550.
24. de Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med 2011; 364:2439-2450.
25. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico (GISSI) Prevenzione. Circulation 2002; 105:1897-1903. (Pubitemid 34437615)
26. Roth EM, Harris WS. Fish oil for primary and secondary prevention of coronary heart disease. Curr Atheroscler Rep 2010; 12:66-72.
27. Marchioli R, Aldegheri MO, Borghese L, et al. Time course analysis of the effect of n-PUFA on fatal and nonfatal arrhythmias in heart failure: secondary results of the GISSI-HF trial. Eur Heart J 2009; 30(Abstract Suppl):165.
28. Finzi AA, Latini R, Barlera S, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. Am Heart J 2011; 161:338.e1-343.e1.
29. Rupp H, Rupp TP, Alter P, Maisch B. Failure of omega-3 fatty acids in atrial fibrillation? No deficiency of highly unsaturated fatty acids in the absence of heart failure. Europace 2011; 139:1357.
30. Saravanan P, Davidson NC. The role of omega-3 fatty acids in primary prevention of coronary artery disease and in atrial fibrillation is controversial. JACC 2010; 55:410-411.
31. Saravanan P, Bridgewater B, West AL, et al. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 2010; 3:46-53.
32. Calò L, Martino A, Sciarra L, et al. Upstream effect for atrial fibrillation: still a dilemma? PACE 2011; 34:111-128.
33. Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol 2010; 381:207-219.
34. Berry JD, Prineas RJ, van Horn L, et al. Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol 2010; 105:844-848.
35. Shen J, Johnson VM, Sullivan LM, et al. Dietary factors and incident atrial fibrillation: the Framingham Heart Study. Am J Clin Nutr 2011; 93:261-266.
36. Heidarsdottir R, Arnar DO, Skuladottir GV, et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 2010; 12:356-363.
37. Leó n H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. Br Med J 2008; 337:a2931.
38. Brouwer IA, Raitt MH, Dullemeijer C, et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J 2009; 30:820-826.
39. Kowey PR, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 2010; 304:2363-2372.
40. Moertl D, Hammer A, Steiner S, et al. Dose-dependent effects of omega-3 polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 2011; 161:915.e1-915.e9.
41. Mozaffarian D, Bryson CL, Lemaitre RN, et al. Fish intake and risk of incident heart failure. J Am Coll Cardiol 2005; 45:2015-2021. (Pubitemid 40814125)
42. Investigators GISS-HF, Tavazzi L, Maggioni AP, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (GISSI-HF): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1223-1230.
43. Levitan EB, Wolk A, Mittleman MA. Fatty fish, marine omega-3 fatty acids, and incidence of heart failure. Eur J Clin Nutr 2010; 64:587-594.
44. Belin RJ, Greenland P, Martin L, et al. Fish intake and the risk of incident heart failure: the Women's Health Initiative. Circ Heart Fail 2011; 4:404-413.
45. Goodfellow J, Bellamy MF, Ramsey MW, et al. Dietary supplementation with marine omega-3 fatty acids improves systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000; 35:265-270. (Pubitemid 30125512)
46. Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009; 91:791-795.
47. Nodari S, Triggiani M, Campia U, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011; 57:870-879.
48. Cowie MR, Cure S, Bianic F, et al.Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UKsetting. Eur J Heart Fail 2011; 13:681-689.
49. Gasparyan AY. Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag 2010; 6:109-112.
50. Nomura S, Inami N, Shouzu A, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemia, diabetic patients. Platelets 2009; 20:16-22.
51. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after PCI to modify responsiveness to dual antiplatelet) study. J Am Coll Cardiol 2010; 55:1671-1678.
52. Cohen MG, Rossi JS, Garbarino J, et al. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel. Thromb Res 2011; doi: 10.1016/j.thromres.2011.04.023.
53. Gajos G, Zalewski J, Rostoff P, et al. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI Clot). Arterioscler Thromb Vasc Biol 2011; 31:1696-1702.